Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.64 |
| ▸ | AOC3 | Q16853 | 13/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17082855 | 0.82 | KCNH2 (0.72) | KCNH2AOC3CYP19A1 | |
| SCHEMBL16053366 | 0.78 | AOC3 (0.75) | KCNH2AOC3 | |
| SCHEMBL16052934 | 0.78 | KCNH2 (0.70) | KCNH2AOC3CYP19A1 | |
| SCHEMBL16053198 | 0.78 | KCNH2 (1.00) | KCNH2AOC3CYP19A1 | |
| SCHEMBL16048095 | 0.76 | AOC3 (1.00) | KCNH2AOC3CYP19A1 | |
| SCHEMBL16048645 | 0.75 | AOC3 (1.00) | KCNH2AOC3 | |
| SCHEMBL30026128 | 0.75 | AOC3 (1.00) | KCNH2AOC3 | |
| SCHEMBL16053209 | 0.74 | AOC3 (0.76) | KCNH2AOC3CYP19A1 | |
| SCHEMBL16053600 | 0.74 | AOC3 (0.70) | KCNH2AOC3 | |
| SCHEMBL16053430 | 0.74 | AOC3 (1.00) | KCNH2AOC3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | claimed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | claimed |
| CN-111032029-A | Vascular adhesion protein-1 inhibitors for the prevention or treatment of migraine | 普罗克斯马根有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| EP-3634393-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | PROXIMAGEN, LLC (US) | 2020-04-15 | — | — | EP | claimed |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2019-10-01 | — | — | US | claimed |
| WO-2018224837-A1 | INHIBITORS OF VASCULAR ADHESION PROTEIN-1 FOR USE IN PREVENTION OR TREATMENT OF MIGRAINE | Proximagen Group Limited (GB) | 2018-12-13 | — | — | WO | claimed |
| US-9951068-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PROXIMAGEN LIMITED (GB) | 2018-04-24 | — | — | US | claimed |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-08-31 | — | — | US | claimed |
| EP-2970260-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | Proximagen Limited (GB) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | claimed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2015189534-A1 | VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY | PROXIMAGEN LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | KCNH2 1764/4885AOC3 55/4885CYP19A1 3624/4885 |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | KCNH2 364/4885AOC3 10/4885CYP19A1 2071/4885 |
| US-10428066-B2 | Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | KCNH2 364/4885AOC3 10/4885CYP19A1 2071/4885 |
| US-20170247378-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, SSB, XDH | KCNH2 364/4885AOC3 10/4885CYP19A1 2071/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | KCNH2 448/4885AOC3 7/4885CYP19A1 995/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | KCNH2 1505/4885AOC3 4/4885CYP19A1 3326/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | KCNH2 2492/4885AOC3 85/4885CYP19A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.